Cargando…
Bioengineered angiotensin-converting-enzyme-2: a potential therapeutic option against SARS-CoV-2 infection
The recombinant soluble human angiotensin-converting enzyme 2 (rshACE2) is a promising therapy against SARS-CoV-2 infection, but it has some drawbacks that reduce the success of its clinical applications. The bioengineered ACE2 (Tag-sACE2 and probiotic-ACE2) as a way may overcome its therapeutic lim...
Autor principal: | Maiti, Biplab K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589099/ https://www.ncbi.nlm.nih.gov/pubmed/34773078 http://dx.doi.org/10.1038/s41371-021-00636-y |
Ejemplares similares
-
Angiotensin-converting enzyme 2 (ACE2) receptor and SARS-CoV-2: Potential therapeutic targeting
por: Sharifkashani, Sourena, et al.
Publicado: (2020) -
Angiotensin-Converting Enzyme 2 Expression and Severity of SARS-CoV-2 Infection
por: Alabsi, Sarah, et al.
Publicado: (2023) -
Exploring the Mystery of Angiotensin-Converting Enzyme II (ACE2) in the Battle against SARS-CoV-2
por: Sharma, Divakar, et al.
Publicado: (2021) -
The renin-angiotensin system and specifically angiotensin-converting enzyme 2 as a potential therapeutic target in SARS-CoV-2 infections
por: Ferrara, Francesco, et al.
Publicado: (2021) -
Relating angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers with incidence or mortality of COVID‐19
por: Wong, Martin C.S., et al.
Publicado: (2020)